Dipylon puts $3.8m into heart monitor launch
This article was originally published in Clinica
Swedish heart monitoring device company Dipylon Medical has secured SKr27.5m ($3.8m) in a series A financing round. The capital, which was provided by Dipylon's manufacturing and technology licensing partner CMA Microdialysis, will go towards the initial launch of the Dipylon cardiac catheter. The product was CE marked in January, and is designed to provide continuous metabolic measurements of the heart muscle inside the coronary sinus. The new capital will also be used to support more extensive international studies of the technology. Prior to this round, Solna-based Dipylon had received SKr0.5m in seed funding from business angel group Escritura.